Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318136 | 1.00 | P2RX7 (0.55) | P2RX7CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL1144126 | 0.86 | P2RX7 (0.57) | P2RX7ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL1144124 | 0.86 | P2RX7 (0.57) | P2RX7ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL1143803 | 0.85 | SYK (0.60) | P2RX7CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL1143806 | 0.85 | SYK (0.60) | P2RX7CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL3334002 | 0.85 | TSHR (0.53) | P2RX7CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL3333993 | 0.85 | TSHR (0.53) | P2RX7CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL2538849 | 0.85 | PPARA (0.60) | P2RX7CTSSALDH1A1CYP1A2POLB | |
| SCHEMBL2538853 | 0.85 | PPARA (0.60) | P2RX7CTSSALDH1A1CYP1A2POLB | |
| SCHEMBL317118 | 0.84 | P2RX7 (0.56) | P2RX7P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | P2RX7 11/4885CTSK 4261/4885CTSL 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.